Drug intelligence / Profile preview

candesartan + metoprolol

Development stage
Unknown
Lead developer
AstraZeneca
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

Candesartan + metoprolol is a combination of two antihypertensive agents used together to manage high blood pressure and heart failure. Candesartan is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to the type-1 angiotensin II receptor (AT1), inhibiting vasoconstriction and aldosterone secretion, which leads to decreased blood pressure[8]. Metoprolol is a beta-1 adrenergic receptor antagonist (beta-blocker) that reduces cardiac output by decreasing heart rate and contractility, thereby lowering blood pressure and reducing myocardial oxygen demand[4]. This combination targets different mechanisms in cardiovascular regulation, providing additive or synergistic effects for conditions such as hypertension and heart failure[2][5].

Other names
candesartan cilexetilmetoprolol tartratemetoprolol succinate
02

Targets

ADRB1 (β1)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on candesartan + metoprolol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on candesartan + metoprolol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call